Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

CureVac deal takes EU's COVID vaccine supplies close to two billion

Published 16/11/2020, 15:13
Updated 16/11/2020, 16:25
© Reuters. FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

© Reuters. FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

By Francesco Guarascio

BRUSSELS (Reuters) - The European Union has struck a deal for up 405 million doses of German biotech firm CureVac's (DE:5CV) potential COVID-19 vaccine, the head of the EU executive said on Monday, taking total supplies secured by the bloc to nearly 2 billion doses.

The deal with CureVac follows EU supply agreements with AstraZeneca (L:AZN), Johnson & Johnson (N:JNJ), Sanofi (PA:SASY), and Pfizer (N:PFE) for a combined 1.4 billion doses of their potential vaccines.

"I am glad to announce a new agreement to buy up to 405 million doses of a vaccine produced by the European company CureVac," European Commission President Ursula von der Leyen said, adding the contract was negotiated after EU funding to the company to develop its vaccine.

The EU, with a population of about 450 million, has been in talks with CureVac for its experimental COVID-19 vaccine at least since July, an internal EU document seen by Reuters shows, confirming an exclusive Reuters report.

The deal will be authorised by the Commission on Tuesday, von der Leyen said, while the actual signature will take place some days later.

Under advance purchase agreements negotiated by the EU during the pandemic, the bloc makes a non-refundable down payment to a vaccine maker to secure a certain number of doses for an agreed price, which will then be paid by EU states willing to buy the shot only after it is authorised as safe and effective by the EU drugs regulator.

The price agreed for the vaccine has not been disclosed.

The deal will initially cover 225 million doses, with an option to buy another 180 million.

CureVac was not immediately available for comment.

The Commission president also said she hoped to finalise a deal soon with Moderna (O:MRNA) for its COVID-19 vaccine, which on Monday announced positive interim results from large-scale clinical trials.

© Reuters. FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

CureVac's approach is based on so-called messenger RNA (mRNA), pieces of genetic code that prompt human cells to produce therapeutic proteins - the same technology used by Moderna and also Pfizer/BioNTech, the other major potential vaccine to have reported positive late-stage trial results.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.